The AhelixBio PTK2 Knockout Cell Line (A549) is a stable, clonal cell line generated via CRISPR/Cas9 technology to induce a complete loss of function of the PTK2 gene (encoding Focal Adhesion Kinase 1, FAK) in the A549 human lung adenocarcinoma background.
This model is essential for studying integrin-mediated signal transduction, cell migration, epithelial-mesenchymal transition (EMT), and the role of FAK in non-small cell lung cancer (NSCLC) progression.
Why PTK2 (FAK)?
Cancer Biology: Studies show that PTK2 amplification is associated with poor prognosis in NSCLC patients. Knockout of PTK2 severely attenuates in vivo tumorigenicity and metastatic activity .
Inflammation: FAK knockdown has been shown to reduce LPS-induced inflammatory injury in A549 cells via inactivation of Wnt and NF-κB pathways .
Cell Plasticity: FAK is a critical mediator of the FAK/AKT signaling pathway, regulating vasculogenic mimicry (VM) and cytoskeleton transformation in lung cancer .
Q: Is this the same as PTK2B?
A: No. This line targets PTK2 (FAK) . PTK2B (PYK2) is a different isoform. Please verify your target gene before ordering .
Q: How do I culture these cells?
A: Follow standard A549 culture protocols. Use F12K medium + 10% FBS . Cells are adherent and epithelial-like. Passage at a ratio of 1:3 to 1:4.
Q: What is the difference between this and a siRNA knockdown?
A: This is a stable knockout. The gene is permanently disrupted, whereas siRNA offers only transient knockdown. This cell line eliminates variability in gene silencing between experiments.
